The scale of the donation reflects an unusual fundraising model in which corporate giving amplifies grassroots employee participation. This year’s campaign included more than $766,000 in contributions from employees of the Energy Transfer family of partnerships, which the company matched with corporate funds at a rate of 50 percent. Since the effort began in 2014, employees have led fundraising initiatives that have resulted in more than $20 million donated to UT MD Anderson, and the combined total of company support now exceeds $21 million. That longevity matters in biomedical research, where multi-year funding streams allow laboratories to plan experiments, retain specialized staff, and pursue lines of investigation that may take years to bear fruit.

Leadership at Energy Transfer framed the gift as an expression of a shared institutional mission rather than a one-time gesture. Tom Long, co-Chief Executive Officer of Energy Transfer, said the commitment employees have shown to UT MD Anderson over the years reflects a shared belief in the power of innovation to change lives. He noted that the breakthroughs happening at the cancer center, and the hope they bring to patients and their families, reinforce the importance of the collaboration. Such statements underscore a growing trend in which private companies channel philanthropic resources toward translational biomedical science, bridging gaps that conventional grant funding does not always cover.

At MD Anderson, the funds arrive at a moment when pediatric oncology is undergoing a significant transformation. Childhood cancers are, in many respects, distinct diseases from their adult counterparts, driven by different genetic alterations and arising in tissues that are still developing. That biological reality means that treatments designed and tested primarily in adults cannot simply be transplanted into pediatric care without careful adaptation. Researchers in pediatric divisions therefore focus on identifying the molecular vulnerabilities unique to childhood tumors, developing age-appropriate dosing and treatment protocols, and minimizing the long-term side effects that can follow young patients for decades after they are declared cancer free.

Richard Gorlick, M.D., division head and chair of Pediatrics at UT MD Anderson, emphasized the role that sustained private generosity plays in that enterprise. He said that Energy Transfer, Sunoco and USA Compression employees continue to demonstrate an extraordinary commitment to children and families facing cancer, and that their generosity helps researchers pursue new discoveries and translate those advances into better treatments and outcomes for patients across the country. The language of translation is significant: moving a laboratory finding, such as the identification of a drug target or a new biomarker, into a clinically validated therapy requires resources that sit outside the standard cycle of federal research grants, particularly during the early and risky stages of development.

The human dimension of that research pipeline was on display in this year’s campaign through its patient ambassador, Braeden Cochran, whose medical journey illustrates how clinical research can change the trajectory of a young life. Cochran was diagnosed as a college freshman with a rare sub-type of blood cancer known as non-Hodgkin B-cell lymphoma, a disease in which immune cells called B cells grow uncontrollably. He began treatment at UT MD Anderson in 2024, a point he describes as a turning point in his care. Now 21, he has become a public face of the fundraising effort, demonstrating to employee donors the concrete consequences of their contributions.

Cochran’s treatment included participation in an immunotherapy-based clinical trial, an approach that has reshaped the treatment landscape for several blood cancers in recent years. Immunotherapy works differently from conventional chemotherapy: rather than directly poisoning rapidly dividing cells, it recruits or engineers the patient’s own immune system to recognize and attack malignant cells. For patients, this can mean the ability to tolerate comprehensive treatment protocols more effectively, with different and often more manageable side effects than those associated with intensive traditional regimens. Cochran credited the trial with enabling him to better tolerate his full course of treatment, an outcome that reflects the careful design work that goes into matching patients with experimental approaches suited to their disease.

Equally telling is what Cochran said about the environment in which he received care. He recalled that he did not really have the same confidence in his own healing until he came to UT MD Anderson, and that was where things really started to turn around for him. He described the experience of standing in his hospital room and seeing the research buildings on the same campus just outside, noting that it was encouraging to know that work on new treatments was being done all the time. That physical proximity between bedside and laboratory is a defining feature of comprehensive cancer centers, where clinicians and researchers operate in parallel and patient needs can inform research priorities in near real time.

Today, Cochran is cancer free and back in school, an outcome he attributes to the advanced lifesaving treatment options and expert care he received at the institution. Stories of this kind carry weight beyond their emotional resonance. For the thousands of employees who participate in the annual giving campaign, a named ambassador provides a tangible connection between payroll deductions and scientific progress, and for the researchers who depend on philanthropic support, patient outcomes serve as the clearest possible justification for continued investment in early-stage and high-risk science.

The $2.2 million gift thus arrives as both a financial milestone and a case study in how modern cancer research is funded. Federal agencies remain the largest source of basic biomedical research support, but philanthropy increasingly fills critical roles: seeding pilot studies, supporting clinical trials that test novel immunotherapy approaches, funding young investigators, and sustaining the infrastructure that allows discoveries to move from bench to bedside. With more than $21 million contributed since 2014 and this year’s record total, the Energy Transfer family of partnerships has built one of the more enduring corporate-employee philanthropic partnerships in pediatric oncology. For the children and young adults treated at UT MD Anderson, and for the researchers racing to develop the next generation of therapies, the donation represents something more than a number: it is continued momentum for a scientific enterprise whose ultimate measure is measured in patients who, like Cochran, return to their studies and their lives after cancer.

Subject of Research: Philanthropic funding of pediatric cancer research and immunotherapy clinical trials at UT MD Anderson Cancer Center

Article Title: Energy Transfer and Sunoco donate $2.2 million to support pediatric cancer research at UT MD Anderson

Article References: Energy Transfer and Sunoco donate $2.2 million to support pediatric cancer research at UT MD Anderson. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pediatric cancer, MD Anderson, Energy Transfer, Sunoco, philanthropy, immunotherapy, clinical trial, non-Hodgkin lymphoma, employee giving campaign, cancer research funding, pediatric oncology, translational research